XtalPi AI Enables Seven-Month PCC Nomination for Viva-Thera's MPER-Targeting HIV-1 Program
PR Newswire (AI)en
PR Newswire (AI)
AI Global WireViva-Thera combines its first atomic-resolution MPER-TMD-CT structure with XtalPi's AI and automation platform to advance a small-molecule PCC. MPER vaccine immunogens elicit antibody levels ...
This is a short summary published by AI Global Wire. The full article is owned and hosted by PR Newswire (AI) — open it there to read it in full.
Read the full story at PR Newswire (AI)Related AI news
- Carnegie China: China passed the US as the top destination for elite AI talent in 2025, rising from 2022's 27.1% share to 40.6%; the US fell from 46.4% to 34.2% (Claudia Chong/The Information)Techmeme · September 23, 2026
- Verizon to invest $70 million in AI training effortEconomic Times Tech · September 23, 2026
- OpenAI gives cyber defence tools to UkraineBBC Technology · September 23, 2026
- Ekai raises $1.7M to give enterprise AI agents verified business contextSiliconANGLE · September 23, 2026
- Vild robot-video vækker opsigt: Ekspert spotter hurtigt afslørende detaljeIngeniøren · September 23, 2026
- The UK CMA proposes rules requiring Google and Android OEMs to offer search choice screens on first use and via yearly prompts, new AI assistant rules, and more (Steve Dent/Engadget)Techmeme · September 23, 2026